Supportive Care Unit, Medical Oncology Department, Georges Pompidou European Hospital, Paris, France
Florian Scotte, Isabelle Borget, Alexandre Vainchtock, Nicolas Martelli
Background: Venous thromboembolic event (VTE) is a common complication for cancer patients, leading to hospitalizations that increase the burden of cancer management. We evaluated the incidence and costs of VTE-related hospitalizations for patients with breast or prostate cancer, two of the most frequent cancers in France. Methods: We used the French national hospital database (PMSI) to select new patients with BC or PC in 2010, who had at least one VTE-related hospitalization during the following two years. VTE-related stays and patients were identified using the disease-specific ICD-10 codes. Hospital costs were estimated from the healthcare system perspective and included care, treatments, accommodation/investment costs and medical/technical procedures, using the French official tariffs. Results: Among 107,916 new patients with BC or PC, 2,268 were hospitalized for a VTE, representing an overall of 2,814 admissions. VTE was classified as primary or related diagnosis (PD/RD) in 1,004 (36%) admissions. Among those PD/RD admissions, pulmonary embolism was the most frequent diagnosis as it led to 626 (62%) stays. Deep venous thrombosis was the second cause of hospitalization (248 admissions; 25% of PD/RD admissions). Re-hospitalisation for recurrence was frequent, as it occurred 546 cases (19.4%) of all VTE-related hospitalizations. For a patient who did not experience recurrence, the mean cost per patient was €3,302 and €3,611 for BC and PC patients respectively. But this amount was highly increased for patients with recurrent VTE, to €5,545 per BC patient and €5,692 per PC patient. Finally, VTE-related hospitalizations were responsible for an overall expenditure of €3.40 million over two years, including €335,000 due to recurrent events. Conclusions: In cancer patients, VTE-related hospitalizations remain frequent and induce an elevated cost. Adequate prophylaxis and management could be an efficient way to reduce the incidence of this common complication and its economic burden.
With one VTE only | With recurrent VTE | |
---|---|---|
Annual cost per breast cancer patient | € 3,302 | € 5,545 |
Annual cost per prostate cancer patient | € 3,611 | €5,692 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Ankushi Sanghvi
2015 ASCO Annual Meeting
First Author: Florian Scotte
2023 ASCO Breakthrough
First Author: Se Hyun Paek
2015 Palliative and Supportive Care in Oncology Symposium
First Author: Isabelle Borget